Literature DB >> 6441641

Plasma pharmacokinetics and tissue distribution of thiotepa in mice.

M J Egorin, S R Akman, P L Gutierrez.   

Abstract

We defined the plasma and tissue concentrations and pharmacokinetics of thiotepa in 22.8-29.3-g male Swiss-Webster mice injected iv with thiotepa at a dose of 5 mg/kg. Concentrations of thiotepa in ethyl acetate extracts of tissue and plasma were determined by gas chromatography. Plasma concentrations of thiotepa declined in a biexponential fashion that was well-described by the equation: Ct = 52.03e-3.36t + 3.10e-0.072t, indicating an alpha-half-life of 0.21 mins and a beta-half-life of 9.62 mins. Thiotepa was rapidly and extensively distributed through the tissues studied and was not concentrated in any particular tissue, although the liver consistently contained concentrations of thiotepa much lower than any other tissue studied. By 1 hr after injection, there was little thiotepa in plasma or any tissue.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6441641

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


  7 in total

1.  Influence of the tissue distribution of ThioTEPA and its metabolite, TEPA, on the response of murine colon tumours.

Authors:  M C Bibby; B J McDermott; J A Double; R M Phillips; P M Loadman; L Burgess
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

2.  ThioTEPA pharmacokinetics during intravesical chemotherapy and the influence of Tween 80.

Authors:  J R Masters; B J McDermott; W E Jenkins; E Fenwick; P J Shah; A R Mundy; P M Loadman; M C Bibby
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Metabolism and alkylating activity of thio-TEPA in rat liver slice incubation.

Authors:  B Hagen; O Dale; G Neverdal; S Azri; O G Nilsen
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  Integrated Population Pharmacokinetic Model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction.

Authors:  Milly E de Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-04       Impact factor: 2.745

5.  Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma.

Authors:  Yi-Bin Chen; Tracy Batchelor; Shuli Li; Ephraim Hochberg; Mark Brezina; Sooae Jones; Candice Del Rio; Morgan Curtis; Karen K Ballen; Jeffrey Barnes; Andrew S Chi; Jorg Dietrich; Jessica Driscoll; Elizabeth R Gertsner; Fred Hochberg; Ann S LaCasce; Steven L McAfee; Thomas R Spitzer; Lakshmi Nayak; Philippe Armand
Journal:  Cancer       Date:  2014-09-09       Impact factor: 6.860

6.  On the search for new anticancer drugs 14: the plasma pharmacokinetics and tissue distribution of spin-labeled thio-TEPA (SL-O-TT).

Authors:  P L Gutierrez; B E Cohen; G Sosnovsky; T A Davis; M J Egorin
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 7.  How to Treat Involvement of the Central Nervous System in Hemophagocytic Lymphohistiocytosis?

Authors:  AnnaCarin Horne; Ronny Wickström; Michael B Jordan; E Ann Yeh; Ahmed Naqvi; Jan-Inge Henter; Gritta Janka
Journal:  Curr Treat Options Neurol       Date:  2017-01       Impact factor: 3.598
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.